irblog.prnewswire.com

BRIXADI® (buprenorphine) Extended-Release Injection for Subcutaneous Use (CIII) is Now Available in the U.S. for the Treatment of Moderate to Severe Opioid Use Disorder

BRIXADI is now available for healthcare settings and pharmacies through a restricted distribution program called the BRIXADI REMS and is administered only by a healthcare professional. PLYMOUTH ...
Healthline

All About Brixadi

Brixadi (buprenorphine) is a prescription drug that’s used to treat opioid use disorder (OUD). Brixadi comes as a liquid solution in a prefilled syringe. You’ll receive Brixadi as an injection under ...
streetinsider

Braeburn's BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder

BRIXADI is the first and only long-acting buprenorphine injectable with both weekly and monthly doses. Patients currently on a transmucosal buprenorphine-containing product can be switched to an ...
Healio

FDA approves extended-release buprenorphine injection for opioid use disorder

Please provide your email address to receive an email when new articles are posted on . Brixadi is the first long-acting buprenorphine injectable that is available in weekly and monthly doses.
Seeking Alpha

Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder

Brixadi is the first treatment for opioid use disorder in the US with both weekly and monthly dosing Three million people in the US diagnosed with opioid use disorder LUND, Sweden, May 24, 2023 ...
irblog.prnewswire.com

Braeburn Submits Request for Final Approval of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder

PLYMOUTH MEETING, Pa., June 1, 2020 /PRNewswire/ -- Braeburn announces that it has requested final approval from the U.S. Food and Drug Administration (FDA) of the New Drug Application for BRIXADI™ ...
Healio

FDA tentatively approves certain forms of Brixadi for opioid use disorder

Please provide your email address to receive an email when new articles are posted on . The FDA tentatively approved certain Brixadi injections for treatment of moderate to severe opioid use disorder, ...